Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity

BACKGROUND: New biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) all showed greater clinical benefits in the treatment of patients with rheumatoid arthritis (RA) with high disease activity, but imposed higher costs than s...

Descripción completa

Detalles Bibliográficos
Autores principales: Prawjaeng, Juthamas, Leelahavarong, Pattara, Budtarad, Nuttakarn, Pilasant, Songyot, Chanjam, Chonticha, Katchamart, Wanruchada, Narongroeknawin, Pongthorn, Kitumnuaypong, Tasanee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230705/
https://www.ncbi.nlm.nih.gov/pubmed/37259090
http://dx.doi.org/10.1186/s12913-023-09595-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230705/
https://www.ncbi.nlm.nih.gov/pubmed/37259090
http://dx.doi.org/10.1186/s12913-023-09595-1

Ejemplares similares